Adverum Biotechnologies, Inc.
ADVMAdverum Biotechnologies, Inc. (formerly known as Avalanche Biotechnologies) is a publicly traded clinical stage gene therapy company located in Redwood City, California. It is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD).
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
6E11 vg/eye of ADVM-022 | Phase 2 | Diabetic Macular Edema | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Adverum Biotechnologies, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Adverum Biotechnologies, Inc.'s (ADVM) pipeline across Phase 2. Its lead program is 6E11 vg/eye of ADVM-022 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Adverum Biotechnologies, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Adverum Biotechnologies, Inc. (ADVM) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ADVM biotech catalysts?→
Add ADVM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Adverum Biotechnologies, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.